Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial

Lancet

Volumn 363, Issue 9426, 2004, Pages 2049-2051

  Weber, Michael A ^c   Julius, Stevo ^a   Kjeldsen, Sverre E ^a,b   Brunner, Hans R ^d   Ekman, Steffan ^f   Hansson, Lennart ^e   Hua, Tsushung ^f   Laragh, John H ^g   McInnes, Gordon T ^h   Mitchell, Lada ^f   Plat, Francis ^f   Schork, M Anthony ^a   Smith, Beverly ^f   Zanchetti, Alberto ⁱ  

^a UNIVERSITY OF MICHIGAN   (United States)

^b ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^c STATE UNIVERSITY OF NEW YORK   (United States)

^d UNIVERSITY OF LAUSANNE   (Switzerland)

^e UPPSALA UNIVERSITY   (Sweden)

^f NOVARTIS PHARMA AG   (Switzerland)

^g WEILL CORNELL MEDICAL CENTER   (United States)

^h UNIVERSITY OF GLASGOW   (United Kingdom)

ⁱ UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANTIHYPERTENSIVE AGENT; HYDROCHLOROTHIAZIDE; VALSARTAN;

ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; HEART FAILURE; HEART INFARCTION; HIGH RISK POPULATION; HOSPITAL ADMISSION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STROKE; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME;

EID: 2942695964     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(04)16456-8     Document Type: Article

References (7)

1. Julius S, Kjeldsen SE, Weber MA, et al for the VALUE Trial Group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. Published online June 14, 2004. http://image.thelancet.com/extras/04art4187web. pdf
2. Staessen JA, Wang J-G, Thijs L. Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003. J Hypertens. 21:2003;1055-1076
3. Furberg CD, Wright JT, Davis BR, et al. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 288:2002;2981-2997
4. Mann J and Julius S, for the VALUE Trial Group. The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial of cardiovascular events in hypertension: rationale and design. Blood Press 1998; 7: 176-183.
5. 2003 European Society of Hypertension. European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003: 21: 1011-1054.
6. The Seventh Report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. JAMA 2003; 289: 2560-2572.
7. Maillard MP, Wurzner G, Nussberger J, Centeno C, Burnier M, Brunner HR. Comparative angiotensin II receptor blockade in healthy volunteers: the importance of dosing. Clin Pharmacol Ther. 71:2002;68-76